Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible Bruton'S Tyrosine Kinase Inhibitor, Vecabrutinib, in B-Cell MalignanciesJohn N. Allan, Jennifer R. Brown, Javier Pinilla Ibarz et al.|Blood|2019Cited by 28
ZUMA-8: A Phase 1 Study of KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Patients With Relapsed/Refractory Chronic Lymphocytic LeukemiaMatthew S. Davids, Javier Pinilla Ibarz, Saad S. Kenderian et al.|Blood|2022Cited by 12